Briobacept Biosimilar – Anti-BAFF fusion protein – Research Grade

Introduction:

Briobacept Biosimilar – Anti-BAFF fusion protein is a novel biologic drug that has been developed as a biosimilar to the anti-BAFF (B-cell activating factor) fusion protein. It is a research grade drug that has shown promising results in pre-clinical studies and is currently undergoing clinical trials for various autoimmune diseases. In this scientific web content, we will discuss the structure, activity and potential applications of Briobacept Biosimilar in detail.

Structure:

Briobacept Biosimilar is a fusion protein composed of two components – the extracellular domain of the human BAFF receptor (BR3) and the Fc region of human IgG1. The extracellular domain of BR3 acts as the targeting moiety, binding to the BAFF protein, while the Fc region provides stability and half-life to the drug. This fusion protein is produced through recombinant DNA technology, ensuring high purity and consistency in its structure and function.

Activity:

BAFF is a cytokine that plays a crucial role in B-cell survival, maturation and activation. In autoimmune diseases, the overproduction of BAFF leads to the proliferation of autoreactive B-cells, resulting in the production of autoantibodies and subsequent tissue damage. Briobacept Biosimilar acts as a competitive inhibitor of BAFF, binding to it and preventing its interaction with the BAFF receptor on B-cells. This blocks the survival and activation signals, leading to the depletion of autoreactive B-cells and reduction of autoantibody production.

Application:

Briobacept Biosimilar has shown promising results in pre-clinical studies for various autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and Sjogren’s syndrome. It has also shown potential in the treatment of B-cell malignancies, such as multiple myeloma and chronic lymphocytic leukemia. In addition to its therapeutic potential, Briobacept Biosimilar can also be used as a research tool for studying the role of BAFF in various diseases and developing new treatment strategies.

Anti-BAFF Antibody:

Briobacept Biosimilar is a fusion protein that acts as an anti-BAFF antibody. Antibodies are proteins produced by the immune system that bind to specific targets, known as antigens. In the case of Briobacept Biosimilar, the BAFF protein is the antigen, and the fusion protein acts as an antibody, binding to and neutralizing its activity. This makes Briobacept Biosimilar a targeted and specific treatment for diseases involving excess BAFF production.

Therapeutic Target:

BAFF has been identified as a therapeutic target in various autoimmune diseases due to its crucial role in B-cell survival and activation. Briobacept Biosimilar specifically targets BAFF, providing a more targeted and effective treatment option compared to non-specific immunosuppressive drugs. By blocking the BAFF signaling pathway, Briobacept Biosimilar has the potential to treat a wide range of autoimmune diseases with minimal side effects.

Conclusion:

In conclusion, Briobacept Biosimilar – Anti-BAFF fusion protein is a novel biologic drug with a unique structure and mechanism of action. It acts as an anti-BAFF antibody and targets BAFF, a key cytokine involved in autoimmune diseases and B-cell malignancies. With its promising results in pre-clinical studies and ongoing clinical trials, Briobacept Biosimilar has the potential to become a valuable treatment option for various diseases and a valuable research tool for understanding the role of BAFF in health and disease.

ProteoGenix catalogue number PX-TA2006. For research use only.

Target: Briobacept Biosimilar – Anti-BAFF fusion protein – Research Grade; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet